Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers - PubMed
3 hours ago
- #PROTAC
- #Cancer Therapy
- #SMARCA2 Degrader
- Discovery of SMD-6346, a potent, selective, and orally active SMARCA2 degrader for SMARCA4-deficient cancers.
- SMD-6346 shows high potency against SMARCA2 (DC50 = 3.3 nM) with minimal activity against SMARCA4, effectively inhibiting growth in SMARCA4-deficient cell lines.
- Exhibits excellent pharmacokinetics, 61% oral bioavailability in mice, and robust tumor growth inhibition in SMARCA4-deficient xenograft models.